Enanta Pharmaceuticals | ENTA - Attività Correnti





Attività Correnti Cambiamento Data
AbbVie USD 29.06B 523M 2025-12
Amgen USD 31.48B 2.42B 2026-03
Anika Therapeutics USD 93.56M 9.8M 2026-03
Arrowhead Research USD 1.17B 223.75M 2025-12
AstraZeneca USD 29.61B 890M 2026-03
BioCryst Pharmaceuticals USD 404.35M 48.66M 2025-12
Biogen USD 9.19B 216.3M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Gilead Sciences USD 19.89B 1.05B 2025-12
GlaxoSmithKline GBP 17.76B 251M 2026-03
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Heron Therapeutics USD 238.07M 8.67M 2025-12
Immunic USD 22.87M 16.4M 2025-12
Incyte USD 5.48B 460.36M 2026-03
Insmed USD 1.79B 137.6M 2025-12
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
J&J USD 59.17B 3.55B 2026-03
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
Ligand Pharmaceuticals USD 832.27M 78.35M 2025-12
Merck USD 35.02B 8.5B 2026-03
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Novartis USD 26.61B 3.85B 2026-03
Novavax USD 850.82M 127.46M 2026-03
Pfizer USD 42.82B 76M 2026-03
PTC Therapeutics USD 2.27B 266.14M 2025-12
Roche Holding CHF 38.73B 3.03B 2025-12
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03